TQB2868 + gemcitabine + paclitaxel + anlotinib

TQB2868 + gemcitabine + paclitaxel + anlotinib is a combination regimen under investigation for the treatment of advanced malignant tumors, including metastatic pancreatic cancer. The regimen includes: - **TQB2868**: A bifunctional fusion protein that targets both programmed cell death protein 1 (PD-1) and transforming growth factor-beta (TGF-beta). By blocking PD-1 and neutralizing TGF-beta in the tumor microenvironment, it aims to abrogate immunosuppression, restore T cell activity, enhance immune response, and inhibit tumor proliferation[1][2][4][5]. - **Gemcitabine**: A nucleoside analog used as chemotherapy that inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells. It is commonly used for various solid tumors. - **Paclitaxel**: An antimicrotubule agent that stabilizes microtubules and prevents their disassembly during cell division, resulting in apoptosis. It is widely used in breast cancer and other malignancies[6][8]. - **Anlotinib**: An oral small molecule tyrosine kinase inhibitor targeting multiple receptors involved in angiogenesis (such as VEGFRs), thereby inhibiting tumor blood vessel formation. This combination leverages immune checkpoint inhibition (PD-1 blockade), suppression of immunosuppressive cytokines (TGF-beta), cytotoxic chemotherapy (gemcitabine/paclitaxel), and antiangiogenic therapy (anlotinib) to maximize antitumor efficacy. The regimen is currently being evaluated primarily for metastatic pancreatic cancer but may have broader applications across advanced solid tumors[3][7].